31 results on '"Larimore, Kevin"'
Search Results
2. Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
3. Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses
4. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up
5. Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia
6. Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity
7. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria
8. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
9. B7h-expressing dendritic cells and plasma B cells mediate distinct outcomes of ICOS costimulation in T cell-dependent antibody responses
10. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
11. Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8⁺ T Lymphocytes
12. Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
13. Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
14. Vosoritide for children with achondroplasia: a 60-month update from an ongoing phase 2 clinical trial
15. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia
16. Additional file 1: of Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
17. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
18. Inflammatory monocytes hinder antiviral B cell responses
19. Inflammatory monocytes hinder antiviral B cell responses
20. Interferon-driven deletion of antiviral B cells at the onset of chronic infection
21. Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages
22. Ontogeny of Recognition Specificity and Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10
23. Correction: Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing
24. Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10
25. Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages.
26. Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing
27. Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
28. Interferon-driven deletion of antiviral B cells at the onset of chronic infection
29. Recognition of a Ubiquitous Self Antigen by Prostate Cancer — Infiltrating CD8+ T Lymphocytes.
30. eP151 - Vosoritide for children with achondroplasia: a 60-month update from an ongoing phase 2 clinical trial.
31. Inflammatory monocytes hinder antiviral B cell responses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.